Separately, Deutsche Bank AG set a €16.00 ($18.82) price target on shares of Evotec AG and gave the company a buy rating in a report on Monday, August 7th.
Shares of Evotec AG (EVT) opened at 14.275 on Thursday. The company’s 50-day moving average is €13.26 and its 200-day moving average is €10.75. The firm has a market cap of €1.99 billion and a price-to-earnings ratio of 56.423. Evotec AG has a 12 month low of €4.24 and a 12 month high of €14.65.
COPYRIGHT VIOLATION NOTICE: “Berenberg Bank Reiterates €13.00 Price Target for Evotec AG (ETR:EVT)” was originally posted by Transcript Daily and is owned by of Transcript Daily. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://transcriptdaily.com/2017/08/13/berenberg-bank-reiterates-13-00-price-target-for-evotec-ag-etrevt.html.
Evotec AG Company Profile
Evotec AG provides drug discovery solutions to the pharmaceutical and biotechnology companies, academic institutions, and foundations and not-for-profit organizations worldwide. The company operates through two segments, EVT Execute and EVT Innovate. It offers drug discovery services, such as integrated services, target identification and validation, hit identification, compound management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, cell and protein production, and in vivo and in vitro pharmacology services.
Receive News & Ratings for Evotec AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec AG and related companies with MarketBeat.com's FREE daily email newsletter.